Journal of the American Society of Nephrology, Vol 2, 1279-1284, Copyright © 1992 by American Society of Nephrology

REGULAR ARTICLES

Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine

KS Kamel, JH Ethier, S Quaggin, A Levin, S Albert, EJ Carlisle and ML Halperin
St. Michael's Hospital, Toronto, Ontario, Canada.

Hyperkalemia is commonly encountered in patients who receive a renal transplant and the immunosuppressive drug, cyclosporine. There is also a high incidence of hypertension (which is thought to be due to expansion of the extracellular fluid volume) and hyperchloremic metabolic acidosis in this group of patients. This constellation of findings led to the suspicion of the possibility that their basis might be type II hypoaldosteronism. To test this hypothesis, 12 patients with hyperkalemia (plasma K+, 5.1 +/- 0.2 mmol/L at the time of study) while receiving cyclosporine were studied. Patients who had diabetes mellitus, those receiving drugs known to cause hyperkalemia (e.g., beta blockers, angiotensin-converting enzyme inhibitors, K(+)-sparing diuretics), or those with a serum creatinine greater than 200 mumol/L were excluded. The renal response to hyperkalemia was inappropriate because the transtubular K+ concentration gradient (TTKG) was only 4.3 +/- 0.4 compared with a TTKG of 13 +/- 1, 2 h after 50 mmol of KCl was given to normal subjects. The TTKG, after administration of 200 micrograms of fludrocortisone, was still very low (5.6 +/- 0.6) in the patients compared with that of controls (12 +/- 1). After administration of 250 to 500 mg of acetazolamide to increase the delivery of bicarbonate to the distal nephron, the TTKG rose significantly to 11 +/- 1 in patients on cyclosporine, compared with 17 +/- 1 in the controls.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				S. Henz, M. T. Maeder, S. Huber, M. Schmid, M. Loher, and T. Fehr Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3939 - 3945. [Abstract] [Full Text] [PDF]

				D. F. Balkovetz Opening Pandora's Box in the Tight Junction J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1624 - 1625. [Full Text] [PDF]

				R. N. Formica Jr, A. L. Friedman, M. I. Lorber, J. D. Smith, T. Eisen, and M. J. Bia A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1389 - 1394. [Abstract] [Full Text] [PDF]

				S. C. Hebert, G. Desir, G. Giebisch, and W. Wang Molecular Diversity and Regulation of Renal Potassium Channels Physiol Rev, January 1, 2005; 85(1): 319 - 371. [Abstract] [Full Text] [PDF]

				P. Gross and F. Pistrosch Hyperkalaemia: again Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2163 - 2166. [Full Text] [PDF]

				B. F. Palmer Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System N. Engl. J. Med., August 5, 2004; 351(6): 585 - 592. [Full Text] [PDF]

				M. Tintillier, M. Mourad, O. Devuyst, and E. Goffin Hypokalaemia and hypertension early after kidney transplantation Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1129 - 1132. [Full Text] [PDF]

				A. Schmidt, U. Gruber, G. Bohmig, E. Koller, and G. Mayer The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA Nephrol. Dial. Transplant., May 1, 2001; 16(5): 1034 - 1037. [Abstract] [Full Text] [PDF]

				E. Bello-Reuss, S. Ernest, O. B. Holland, and M. R. Hellmich Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells Am J Physiol Cell Physiol, June 1, 2000; 278(6): C1256 - C1265. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673